Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients

Objectives: This study aimed to explore factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer (aNSCLC) patients treated with immune checkpoint inhibitors (ICIs). Methods: A total of 101 patients with aNSCLC receiving ICIs were included. The association bet...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yahua Wu, Haishan Wu, Mingqiang Lin, Tianxiu Liu, Jiancheng Li
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	Non-small cell lung cancer Immune checkpoint inhibitors Pre-treatment prognostic score Immunotherapy respond Immune-related adverse events Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/e5b99e290dad40368c8d31d424deb3fc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e5b99e290dad40368c8d31d424deb3fc
record_format	dspace
spelling	oai:doaj.org-article:e5b99e290dad40368c8d31d424deb3fc2021-11-20T05:05:13ZFactors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients1936-523310.1016/j.tranon.2021.101268https://doaj.org/article/e5b99e290dad40368c8d31d424deb3fc2022-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S193652332100259Xhttps://doaj.org/toc/1936-5233Objectives: This study aimed to explore factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer (aNSCLC) patients treated with immune checkpoint inhibitors (ICIs). Methods: A total of 101 patients with aNSCLC receiving ICIs were included. The association between clinical factors and multiple endpoints including objective response rate (ORR), disease control rate (DCR), overall survival (OS) and progression-free survival (PFS) were investigated by multivariate analyses. Results: Multivariate logistic analyses revealed that clinical stage, lactate dehydrogena (LDH), and any grade immune-related adverse events (irAEs) were independent predictors of ORR, while LDH and ICIs treatment type were independent predictors of DCR. In Multivariate Cox analysis, Eastern Cooperative Oncology Group performance status (ECOG PS), LDH, albumin (Alb), platelet to lymphocyte ratio (PLR), and any grade irAEs were independent factors for OS. Similarly, clinical stage, LDH, Alb, and any grade irAEs were independent factors for PFS. Pre-treatment prognostic score was established based on clinical stage, ECOG PS, LDH, Alb and PLR to classify patients into three groups: the good group (0–1 score), the intermediate group (2 scores) and the poor group (3-4 scores). The immunotherapy response was significantly different in various prognostic groups. Subset analyses showed pre-treatment prognostic score ≥ 3 tended to have a strong negative impact on survival among patients with programmed cell death-ligand 1 (PD-L1) expression ≥ 50%. Conclusions: Pre-treatment prognostic score based on clinical stage, ECOG PS, LDH, Alb and PLR may help to identify aNSCLC patients who may benefit from ICIs.Yahua WuHaishan WuMingqiang LinTianxiu LiuJiancheng LiElsevierarticleNon-small cell lung cancerImmune checkpoint inhibitorsPre-treatment prognostic scoreImmunotherapy respondImmune-related adverse eventsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENTranslational Oncology, Vol 15, Iss 1, Pp 101268- (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	Non-small cell lung cancer Immune checkpoint inhibitors Pre-treatment prognostic score Immunotherapy respond Immune-related adverse events Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Non-small cell lung cancer Immune checkpoint inhibitors Pre-treatment prognostic score Immunotherapy respond Immune-related adverse events Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Yahua Wu Haishan Wu Mingqiang Lin Tianxiu Liu Jiancheng Li Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients
description	Objectives: This study aimed to explore factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer (aNSCLC) patients treated with immune checkpoint inhibitors (ICIs). Methods: A total of 101 patients with aNSCLC receiving ICIs were included. The association between clinical factors and multiple endpoints including objective response rate (ORR), disease control rate (DCR), overall survival (OS) and progression-free survival (PFS) were investigated by multivariate analyses. Results: Multivariate logistic analyses revealed that clinical stage, lactate dehydrogena (LDH), and any grade immune-related adverse events (irAEs) were independent predictors of ORR, while LDH and ICIs treatment type were independent predictors of DCR. In Multivariate Cox analysis, Eastern Cooperative Oncology Group performance status (ECOG PS), LDH, albumin (Alb), platelet to lymphocyte ratio (PLR), and any grade irAEs were independent factors for OS. Similarly, clinical stage, LDH, Alb, and any grade irAEs were independent factors for PFS. Pre-treatment prognostic score was established based on clinical stage, ECOG PS, LDH, Alb and PLR to classify patients into three groups: the good group (0–1 score), the intermediate group (2 scores) and the poor group (3-4 scores). The immunotherapy response was significantly different in various prognostic groups. Subset analyses showed pre-treatment prognostic score ≥ 3 tended to have a strong negative impact on survival among patients with programmed cell death-ligand 1 (PD-L1) expression ≥ 50%. Conclusions: Pre-treatment prognostic score based on clinical stage, ECOG PS, LDH, Alb and PLR may help to identify aNSCLC patients who may benefit from ICIs.
format	article
author	Yahua Wu Haishan Wu Mingqiang Lin Tianxiu Liu Jiancheng Li
author_facet	Yahua Wu Haishan Wu Mingqiang Lin Tianxiu Liu Jiancheng Li
author_sort	Yahua Wu
title	Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients
title_short	Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients
title_full	Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients
title_fullStr	Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients
title_full_unstemmed	Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients
title_sort	factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/e5b99e290dad40368c8d31d424deb3fc
work_keys_str_mv	AT yahuawu factorsassociatedwithimmunotherapyrespondandsurvivalinadvancednonsmallcelllungcancerpatients AT haishanwu factorsassociatedwithimmunotherapyrespondandsurvivalinadvancednonsmallcelllungcancerpatients AT mingqianglin factorsassociatedwithimmunotherapyrespondandsurvivalinadvancednonsmallcelllungcancerpatients AT tianxiuliu factorsassociatedwithimmunotherapyrespondandsurvivalinadvancednonsmallcelllungcancerpatients AT jianchengli factorsassociatedwithimmunotherapyrespondandsurvivalinadvancednonsmallcelllungcancerpatients
_version_	1718419630561689600

Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients

Ejemplares similares